Co-administration of acid reducing agents (ARAs) with drugs exhibiting pH-dependent solubility can lead to drug-drug interactions mediated by gastric pH changes (pH-dependent DDIs). Physiologically based pharmacokinetic (PBPK) modelling is recognized by the U.S. FDA as an alternative approach to clinical trials for the evaluation of pH-dependent DDIs1. To date, such DDIs have predominantly been assessed […]
